RiverPark Advisors’s Biotech Acquisition Company Class A Ordinary Shares BIOT Stock Holding History

RiverPark Advisors’s Portfolio BIOT Stock Details BIOT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-799,001	Closed	-$8.07M	–	102
2022 Q4	$8.07M	Hold	799,001	–	–	3.85%	2
2022 Q3	$7.93M	Hold	799,001	–	–	2.58%	3
2022 Q2	$7.91M	Hold	799,001	–	–	2.51%	8
2022 Q1	$7.87M	Hold	799,001	–	–	1.44%	24
2021 Q4	$7.86M	Buy	+799,001	New	+$7.84M	0.94%	39

RiverPark Advisors's BIOT Position: Q1 2023 in Review

RiverPark Advisors sold out of Biotech Acquisition Company Class A Ordinary Shares (BIOT) in Q1 2023, closing a stake of 799,001 shares — an estimated $8.07M sold.

RiverPark Advisors first reported a position in BIOT in Q4 2021 and held it in 5 quarters. The position peaked at $8.07M in Q4 2022. 0 funds tracked by Wall St. Rank hold BIOT as of Q1 2023.

RiverPark Advisors reported no remaining Biotech Acquisition Company Class A Ordinary Shares position as of Q1 2023 after selling out during the quarter.
RiverPark Advisors sold 799,001 Biotech Acquisition Company Class A Ordinary Shares shares in Q1 2023, an estimated $8.07M.
RiverPark Advisors first reported a position in Biotech Acquisition Company Class A Ordinary Shares in Q4 2021 and held it in 5 quarters.
RiverPark Advisors's Biotech Acquisition Company Class A Ordinary Shares position peaked at $8.07M in Q4 2022.
0 funds tracked by Wall St. Rank held Biotech Acquisition Company Class A Ordinary Shares as of Q1 2023.

Based on RiverPark Advisors's 13F filing for Q1 2023, filed 3 May 2023.